SEC Form 4 · accession 0001179110-17-010135
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Period of report
Jun 30, 2017
Accepted (ET)
Jul 5, 2017 · 8:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| American Depository Shares representing Common SharesF1,F2 | Jun 30, 2017 | S | 1,775 | $10.9411 | D | 2,583,229 | D | |
| American Depository Shares representing Common SharesF1,F3 | Jul 3, 2017 | S | 11,352 | $10.9452 | D | 2,571,877 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs.
- F2The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.50 to $11.08 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.
- F3The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.59 to $11.12. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.